BACKGROUND: Treatment options for dural arteriovenous fistulas (DAVFs) have expanded with the application of stereotactic radiosurgery (SRS). OBJECTIVE: To assess the role of SRS with or without embolization, we reviewed our entire DAVF experience. METHODS: Between 1991 and 2006, 40 patients with 44 DAVFs underwent Gamma knife SRS. Twenty-eight patients had upfront SRS before or after embolization and 12 patients underwent delayed SRS for recurrent or residual DAVFs after initial embolization. The median patient age was 60 years (range, 29-90). DAVFs were diagnosed in 7 patients after they sustained an intracranial hemorrhage. The median SRS target volume was 2.0 mL (range, 0.2-8.2 mL) and the median marginal dose was 21.0 Gy (range, 15-25 Gy). RESULTS: At a median follow-up of 45 months (range, 23-116 mo), a total of 28 patients (harboring 32 DAVFs) had obliteration confirmed by imaging. We found a 83% obliteration rate in patients who had upfront SRS with embolization and a 67% obliteration rate in patients who only had SRS. One patient died of an intracerebral hemorrhage 2 months after SRS. Cavernous carotid fistulas were associated with higher rates of occlusion (P = .012) and symptom improvement (P = .010) than were transverse-sigmoid sinus-related fistulas. CONCLUSION: When upfront SRS is possible in conjunction with embolization, successful DAVF obliteration is possible in most patients, especially those with carotid cavernous fistulas. SRS should target the entire fistula regardless of whether it precedes or follows embolization. In selected patients with a small-volume, low-risk DAVF, SRS alone is an effective treatment option in most patients.
I
ntracranial dural arteriovenous fistulas (DAVFs) are uncommon vascular malformations wherein dural arteries drain into venous sinuses or leptomeningeal veins. They constitute approximately 10 to 15% of all intracranial vascular malformations. 1 DAVFs may occur anywhere within the dura, but develop most frequently near the transverse, sigmoid, and cavernous sinuses. [1] [2] [3] [4] The treatment of DAVFs depends on the severity of the symptoms, the angiographic characteristics, and the perceived risk for intracranial hemorrhage. The bleeding risk of DAVFs is highly related to leptomeningeal cortical venous drainage and passive venous hypertension. 4 ,5 DAVF classifications have been based on venous drainage patterns defined by conventional angiography. DAVFs with retrograde leptomeningeal venous drainage have a significantly higher risk of intracranial bleeding. 6, 7 Asymptomatic low-risk DAVFs (Borden grade I), can be treated conservatively, unless symptoms of pulsatile tinnitus are disabling to the patient. Most high-risk DAVFs (Borden grade II or III) warrant treatment because they carry a high probability of intracranial hemorrhage or neurological deterioration. 4, 8, 9 Treatment strategies for DAVFs are diverse, including surgical excision, [10] [11] [12] transarterial or transvenous embolization [13] [14] [15] and stereotactic radiosurgery (SRS). [16] [17] [18] [19] [20] [21] [22] In individual cases, successful therapy may involve a combination of more than one approach.
SRS in combination with transarterial embolization is shown to be effective for the treatment of selected patients with DAVFs. 16, [19] [20] [21] 23 We report our experience using SRS for DAVF patients, including those who had embolization before or after SRS.
METHODS AND MATERIALS Patient Population
Forty patients with 44 intracranial DAVFs underwent Gamma knife SRS at the University of Pittsburgh Medical Center between 1991 and October 2006. Table 1 summarizes the patient demographic and treatment data. The series included 22 males and 18 females with a median age of 60 years (range, . The following DAVF locations were noted: carotid cavernous (n = 17, 4 bilateral), transverse sigmoid (n = 18), and other locations (n = 9). The median follow-up interval after SRS was 45 months (range, 23-116 mo).
Three patients had DAVF detected during an imaging evaluation for headache. Thirty-seven patients were symptomatic from their DAVFs related to their location. Eleven of 13 patients with DAVFs located in the carotid-cavernous sinus presented with orbital findings including scleral injection, proptosis, and chemosis. Fifteen of 18 patients with DAVFs located in the transverse-sigmoid sinus had pulsatile tinnitus. Six of 9 patients with DAVFs in other locations received their diagnoses after they experienced an intracranial hemorrhage. Twenty DAVFs had angiographic evidence of cortical venous drainage. Using the Borden DAVF classification 6 we found that 24 DAVFs (55%) were type I and 20 (45%) were type II. Using the Cognard classification 7 we found that 24 DAVFs (55%) were type I, 6 (14%) were type IIa, 6 (14%) were type IIb, and 8 (17%) were type IIa + b.
SRS and Embolization
Twelve patients underwent initial embolization at other centers and had delayed SRS at our center because of incomplete obliteration (n = 8) or recurrent DAVFs (n = 4). Twenty-eight patients had upfront DAVF management at our center. Eleven patients had combined embolization and SRS. Seventeen patients underwent SRS alone because they had either no accessible feeding vessels (n = 5), a distal location of their fistula (n = 4), medical or age comorbidities that posed an unacceptable embolization risks (n = 5), or a low-bleeding-risk DAVF that did not warrant early embolization (n = 3). All patients who underwent combined embolization and SRS at our center had both procedures performed either the same day or the next day. Seven patients received SRS immediately before embolization and 4 patients had embolization before SRS based on the preference of the endovascular team. Six patients underwent SRS after arterial embolization using polyvinyl alcohol particles. Other embolization materials included platinum coils in 3 patients and Onyx (ev3, Inc.) in 3 patients who underwent upfront management in 2006.
SRS was performed with the model U, B, C, or 4-C Leksell Gamma Knife (Elekta Inc, Atlanta, Georgia). The procedure began with application to the head of a model G Leksell stereotactic frame under conscious sedation and local scalp anesthesia. Target detection was performed using high-resolution magnetic resonance imaging (MRI) followed by high-resolution digital subtraction of conventional cerebral angiography. The images were exported to a computer workstation for dose planning. The median prescribed isodose volume was 2.0 mL (range, 0.2-8.2 mL). The median prescription dose delivered to the margin of the DAVF target was 20 Gy (range, 15-25 Gy). The prescription isodose was 50% in 42 fistulas and 60% in 2 fistulas. Maximum dose varied from 30 to 50 Gy (median, 40 Gy).
Follow-Up Evaluation
Patients who underwent both SRS and embolization were admitted for 18 to 24 hours. Patients who underwent SRS alone were discharged the same day. Clinical follow-up and MRI were performed at 6 months after SRS and then annually for 3 years. Angiography was performed to confirm obliteration in all patients with high-risk DAVFs. Angiography was not pursued in low-bleeding-risk DAVFs if their symptoms resolved and if their high-resolution MRI and magnetic resonance angiogram (MRA) showed evidence of obliteration. Such evidence included absence of flow voids on T2-weighted MRI and absence of contrast enhancement of the DAVF target in comparison with the localization MRI performed at the time of SRS.
Statistics and Data Analysis
Univariate analysis was performed using the Fisher exact test with P , .05 set as significant. This retrospective study was approved by the University of Pittsburgh Institutional Review Board.
RESULTS

Clinical Outcomes
Twenty-two patients without cortical venous drainage had low-bleeding-risk DAVFs (Borden type I). Symptomatic improvement was noted in 19 (86%) of these patients. Eighteen patients with cortical venous drainage had a higher risk of bleeding (Borden type II). One patient (a 77-year-old patient with transverse-sigmoid DAVFs, Borden type II, who underwent only SRS because he had no accessible feeding vessels for embolization) had a fatal cerebellar hemorrhage 2 months after the procedure. No patient experienced an embolization complication or sustained an adverse radiation effect during the follow-up period. During the first 6 months after SRS, 4 patients with carotid-cavernous DAVFs had transient worsening of orbital symptoms before obliteration was achieved. We analyzed the relationship between symptom improvement and several different variables, including age, sex, DAVF location, previous hemorrhage, use of embolization, cortical venous drainage, primary or secondary treatment, target volume, maximum dose, and marginal dose. As the only significant findings, we confirmed that DAVFs of the carotid-cavernous sinus were associated with better symptom improvement than DAVFs of the transverse-sigmoid sinus (P = .001).
Imaging Outcomes
Follow-up imaging was available in 39 of 40 patients (one died 2 months after SRS). Among patients with high bleeding risk, 14 of 20 DAVFs (70%) demonstrated complete fistula obliteration at the time of angiography. Among patients with low bleeding risk, 18 of 24 DAVFs (75%) had obliteration confirmed by MRI (n = 11) or angiography (n = 7). We have found that MRI has a 90% specificity for confirmation of obliteration compared with subsequent angiography in arteriovenous malformations that undergo SRS. 24 However, if we hypothesize that angiography always failed to confirm MRI-defined obliteration, then the final obliteration rate of low-risk DAVF (imaged by MRI alone) would decrease to 29%. No low-risk DAVF sustained a bleeding event or other symptoms during the follow-up interval. The imaging defined response (angiography in high-risk patients and MRI with or without follow-up angiography in low-risk patients) related to fistula location is shown in Figure 1 . DAVFs of the carotid-cavernous sinus were associated with better rates of obliteration (P = .012).
Impact of Embolization
Fourteen DAVFs in 12 patients were residual or recurrent after embolization performed elsewhere (and underwent delayed SRS at our center). Thirty DAVFs in 28 patients had no prior management before referral to our center ( Figure 2 ). In the delayed SRS series, 3 of 4 DAVFs with recurrent fistulas had obliteration. Seven of 10 DAVFs with residual fistulas had obliteration. In the upfront series, 12 of 18 DAVFs managed by SRS alone had complete obliteration. Six of 7 DAVFs that underwent SRS followed by embolization were obliterated. Four of 5 DAVFs that underwent embolization followed by SRS had complete obliteration. Figure 3 highlights a patient who FIGURE 1. DAVF obliteration rates related to location. DAVF, dural arteriovenous fistula. underwent embolization followed by SRS but recanalization occurred 4 years later. The SRS target was limited to the residual fistula after embolization, and recannalization developed within the previously embolized component.
DISCUSSION
The natural history of DAVF includes patients whose fistula is demonstrated by imaging but are clinically asymptomatic, patients who have transient symptoms followed by spontaneous thrombosis, patients with persistent symptoms, and patients who have major morbidity or even death from intracranial hemorrhage. The presentation and significance of DAVF depends on its location and cortical venous drainage pattern. 3, 6 Patients with low-bleeding-risk DAVF (those without cortical venous drainage) may have spontaneous thrombosis followed by symptomatic resolution. 4, [25] [26] [27] [28] Asymptomatic low-risk DAVFs can be observed and monitored both clinically and by imaging. However, some DAVF patients with low-hemorrhage-risk fistulas still require prompt treatment if they are associated with disabling pulsatile tinnitus (in the case of transverse sinus fistulas) or ocular symptoms such as exophthalmos or acute chemosis (in the case of cavernous sinus fistulas).
High-bleeding-risk DAVFs-those with cortical venous drainage-warrant prompt intervention. Duffau et al 29 found a 35% risk of repeat intracranial hemorrhage in the first weeks after an initial bleed related to DAVFs. Van Dijk et al 30 reported an annual hemorrhage rate of 8% and an annual mortality rate of 10% from DAVFs with persistent untreated cortical venous drainage. More recently, Soderman et al 9 reported a somewhat lower annual bleeding rate in their high-risk patients. In his report, patients who presented with an intracranial hemorrhage had an annual 7.4% rebleeding risk. In contrast, angiographically confirmed DAVFs with cortical venous drainage (but no preceding bleeding) had an annual bleed risk of 1.5%. If this finding is verified by additional authors, further modification of DAVF treatment strategies may be warranted.
Although transarterial embolization is often effective for DAVFs, past studies indicate that embolization fails to achieve complete and permanent obliteration of the fistula in 50% or more of cases. 31, 32 Complete occlusion can be difficult because not all arterial feeding vessels can be seen during angiography. Superselective catheterization, which may be necessary to identify the myriad of feeding vessels, can also be technically challenging. Inadvertent acute occlusion of feeding or adjacent vessels can result in stroke or hemorrhage. 33 Some patients experience delayed recanalization of the fistula, which restores the risk of a new bleeding event. 4, 34 Direct surgery is a potential option for some patients, especially if there is a limited direct artery-to-vein fistula. Simple clipping may be sufficient to immediately reverse the intracranial venous hypertension characteristic of high-flow fistulas.
11,12,14,35 Lucas and colleagues 14 described skeletonization of the venous sinus to occlude a fistula. Such an approach may not prevent recanalization. 36 However, the overall risks of direct surgical exploration may be higher than embolization preceded or followed by radiosurgery, especially in elderly patients or those with medical comorbidities.
SRS is shown to be an effective treatment for selected patients with DAVFs. [16] [17] [18] [19] [20] 22, 23 In 1994, Lewis et al 37 reported 7 patients with tentorial DAVFs undergoing radiosurgery and embolization; 5 patients had fistula thrombosis, and 2 patients had 50% reduction in fistula flow. One patient had transient radiation injury of the brainstem 15 months after radiosurgery. Since that report, additional evidence of the potential benefit of SRS has emerged (Table 2) .
SRS has also been used alone in the management of DAVFs. In 2002, Pan et al 22 reported that 14 of 19 patients with transverse sigmoid sinus DAVFs had symptom resolution and 11 patients had radiographically confirmed obliteration. More recently, Soderman et al 20 reported 52 patients with 58 DAVFs treated with Gamma knife radiosurgery; 43 of their 52 DAVFs were treated by SRS alone. In this experience, 68% of DAVFs had angiographically proven obliteration and 24% had significant flow regression.
For symptomatic patients or those with cortical venous drainage, embolization offers early symptomatic relief and possible cure. SRS offers the potential for delayed complete fistula closure, especially in patients not eligible for embolization because of high medical risks or poor vascular access to the feeding fistula vasculature (Figure 4) . In the present series 23 patients underwent combined embolization and SRS. We reserve SRS as a single modality of therapy for patients with no or limited cortical venous drainage, for those with only mild symptoms, and for those patients with poor vascular access for embolization. Overall, 17 of 23 patients who underwent both SRS and embolization at some time had complete fistula obliteration.
Angiography was used to confirm obliteration in 21 patients. Eleven patients declined additional angiography and had followup by MRI and MRA alone. All of these 11 patients had lowbleeding-risk DAVFs. Although angiography is a superior diagnostic tool to MRA for confirming DAVFs obliteration, the main goal of treating low-bleeding-risk DAVFs is symptom relief. For low-risk DAVFs we reserve a more invasive procedure such as angiography if the patient's symptoms persist or recur. In contrast, angiography is critical for patients with high-risk DAVFs for whom we need definitive confirmation that the malformation is (and remains) completely occluded.
In our upfront SRS and embolization patients we also evaluated the timing of the embolization procedure relative to the timing of SRS. Six of 7 patients who underwent embolization after SRS had obliteration. Four of 5 patients who had embolization before SRS had obliteration. In this relatively small experience we could not define a statistically significant difference between these 2 management approaches. Dr Thorel Sundt first recommended SRS followed by embolization shortly after the introduction of the Gamma knife at the Mayo Clinic (T. Sundt, personal communication, 1992 ). Friedman et al 16 also recommended that SRS was best performed before endovascular treatment because visualization of the entire target volume could be reduced by previous embolization. It is important to quickly achieve reduction in the DAVF flow to draining cortical veins, and thereby potentially reduce the risk of hemorrhage. Embolization is the modality most likely to accomplish this outcome quickly, if direct surgical removal is considered high risk. Patients will best be managed at a center of excellence where all therapeutic options are available: surgery, radiosurgery, and embolization.
When possible to combine in a planned management strategy, embolization provides early protection from bleeding and SRS facilitates late and long-term closure. In our data, the average latency interval until fistula closure was approximately 23 months. 18 Among 17 patients with 18 DAVFs who received only SRS, 8 DAVFs were low-bleeding-risk DAVFs (Cognard types I and IIa), whereas 10 DAVFs were high-bleeding-risk DAVFs (Cognard types IIb and II a+b). Five of these DAVFs had previous DAVF-related intracranial hemorrhages. Complete obliteration was found in 12 of 18 DAVFs (67%) who had SRS alone. One patient experienced a second (and fatal) hemorrhage soon after SRS. In selected patients, SRS alone may be an acceptable management strategy if their fistula does not have cortical venous drainage or has poor vascular access for embolization. High-risk DAVFs that undergo SRS alone have the potential to bleed during the latency interval, although that risk may diminish even before complete obliteration is documented. Soderman et al 20 reported that the annual bleeding rate for DAVFs after SRS was approximately 2.6%. Other authors emphasize that DAVF obliteration may occur even sooner than obliteration of other intracranial vascular malformations. 20, 22 We observed one patient in our series who received only SRS and had angiographically proven obliteration 7 months after SRS.
DAVF location was the only statistically significant factor that affected both rate of obliteration and symptom improvement. Patients with DAVFs involving the cavernous sinus had a better rate of obliteration and symptom improvement than patients with transverse-sigmoid sinus fistulas. In our literature review we found that DAVFs involving the cavernous sinus had total obliteration rates of 75 to 93%, whereas DAVFs involving the transverse-sigmoid sinus had a 58 to 65% total obliteration rate. [16] [17] [18] [19] [20] [21] [22] [23] The reasons for this difference remain unclear but may reflect difficulties in targeting the shunt or more complex angioarchitecture in patients with transverse sinus fistulas.
In Figure 3 , we suggest a potential treatment algorithm for patients with DAVF. For DAVFs with good vascular access, SRS followed or preceded by embolization has the best early and later obliteration rates. For patients with poor vascular access for embolization, SRS alone is usually an effective option with low complication rates. We recommend that all patients have annual MRIs after SRS. Angiography remains the standard to access treatment response in all patients with DAVFs. However, for patients with no cortical venous drainage and symptomatic improvement, resolution of MRI vascular abnormalities may be a sufficient method to access outcomes. No patient in our experience with MRI evidence of obliteration has sustained a hemorrhage.
CONCLUSION
Combined SRS and embolization provided a generally effective management strategy for DAVFs, including those that recurred after initial embolization. We had one early mortality from a highrisk DAVF with no vascular access for embolization. No patient had embolization or radiation-related morbidity. For selected DAVF patients who are not eligible for embolization, SRS alone is an effective treatment option in most patients. DAVFs that involve the cavernous sinus have higher rates of obliteration and symptom improvement. We suggest that embolization performed immediately before or after SRS (but still targeting the entire fistula volume) provides the best obliteration. Patients with DAVF warrant management at centers where all treatment options exist. If direct surgery is not possible or is considered high risk, embolization provides early benefit and SRS provides late benefit during the management of these relatively rare vascular anomalies.
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COMMENTS
T his study investigates the effects of stereotactic radiosurgery on dural arteriovenous malformations (DAVMs). The authors provide a retrospective analysis of a small mixed population of patients harboring DAVMs mainly of the carotid-cavernous and transverse-sigmoid regions. The population consists of 40 patients harboring 44 DAVMs treated ''upfront'' by radiosurgery with or without embolization, or delayed after previous embolization. Of the 28 patients treated ''upfront,'' 11 underwent radiosurgery with embolization and 17 had radiosurgery alone. Twelve patients with residual or recurrent DAVMs comprised the delayed radiosurgery group, having undergone embolization at an outside institution. Of the entire population, 55% were classified as low risk (Borden type I) and 45% high-risk (Borden type II) DAVMs.
At a mean follow-up of 45 months, the authors report an 83% obliteration rate in the ''upfront'' radiosurgery + embolization group, and a 67% obliteration rate in the ''upfront'' radiosurgery only group. The delayed radiosurgery group is reported as having a 71% obliteration rate. Of note, catheter-based angiographic confirmation of obliteration was available in only 21 of 44 DAVMs. Specifically, in the low-risk Borden type I group, angiographic obliteration was available in 7 of 24 DAVMs with the remaining 11 obliterated DAVMs being assumed from MRI indicators. If one assumes that ''MRI obliteration'' does not correlate with ''angiographic obliteration'' then the rate of success for this group is as low as 29%. Clearly the rate of true obliteration lies somewhere in between, and the authors make valid arguments in not pursuing catheter angiography for low-risk DAVMs. Last, there was one death from hemorrhage in the follow-up period.
This is a well-done, insightful analysis that helps to further delineate the role of radiosurgery in the treatment of DAVMs. The authors provide a thoughtful algorithm and suggest a role for radiosurgical treatment before embolization to truly encompass the entire lesion. While this is reasonable in the routine management of DAVMs, a cautious approach is recommended as many of these patients require urgent treatment to decrease retrograde venous shunting. This can only be achieved via endovascular or surgical means. The obliteration rates are promising and, although I agree that many low-risk DAVMs do not warrant formal angiography, one cannot be completely assured of complete obliteration and elimination of hemorrhage risk by MRI alone. The 67% obliteration rate for those treated exclusively by radiosurgery further stresses the fact that the role of radiosurgery is secondary. Primary treatment remains endovascular and/or surgical. Cavernous sinus fistulas had a significantly better response than fistulas in other locations. Symptomatic improvement was noted in 86% of the symptomatic patients. DAVFs of the carotid-cavernous sinus were associated with better symptom improvement than DAVFs of the transverse-sigmoid sinus (P = .001).
Among high-bleeding-risk patients, 14 of 19 DAVFs (73%) demonstrated complete fistula obliteration at the time of angiography. Among low-bleeding-risk patients, 18 of 24 DAVFs (75%) had obliteration confirmed by MRI or angiography. When radiosurgery was the adjuvant treatment to embolization, the obliteration rate of recurrent DAVFs was 75% and for residual DAVFs it was 70%. When radiosurgery was the initial treatment, DAVFs managed by SRS alone had a 67% complete obliteration rate, whereas DAVFs that underwent SRS followed by embolization had an 86% obliteration rate. DAVFs that underwent initial embolization followed by SRS during the same admission had an 80% obliteration rate. They relate that embolization provided early symptom relief, whereas SRS provided for delayed complete fistula closure.
SRS alone can be the choice when symptoms are mild and the risk of intracranial bleeding is low. Otherwise, embolization should be added to enhance the results of SRS. This approach is more acceptable, hinging on the fact that SRS alone had the lowest obliteration rate (67%) when compared with all the other groups shown in their treatment algorithm. It is also supported by the fact that radiosurgery is not the best choice to obliterate large-volume arteriovenous fistulas; these are better approached by coil or onix embolization. Radiosurgery is better for microvasculature obliteration as it is in compact nidus of arteriovenous malformations of the brain, a situation in which the embolization technique is deficient, mainly when the feeding vessel is not amenable to catheterization. Therefore, radiosurgery and embolization are complementary techniques for dural fistulas.
It is unfortunate that only half of the patients in this study underwent angiography to confirm complete obliteration. The other half underwent MRI/MRA, which are suboptimal techniques to confirm obliteration of dural fistulas. This leaves readers wondering whether half of the patients reported as cured had indeed a complete obliteration and are free from recanalization and possible bleeding in the future. Recently, it was reported that residual DAVFs after radiosurgery were treated by embolization.
1 Long-term follow-up of these patients is necessary to confirm whether they are indeed protected from hemorrhage or novel symptoms.
Taking into account all the limitations of this retrospective, small, and heterogeneous sample with dural arteriovenous fistulas, this is an excellent analysis of the effects of radiosurgery alone or combined with embolization. The authors make many valid points based on their data and review of the literature. They were able to develop a reasonable algorithm to treat these patients with difficult vascular malformations, frequently causing severe symptoms and threatening intracranial bleeding. The suggestion of radiosurgery preceding embolization, previously supported by others in the literature, is important. This rationale provides for complete irradiation of the lesion, mainly when the lesions are small, as was the case in this study. Moreover, it gives the patient the opportunity of early symptomatic relief when embolization immediately follows radiosurgery, circumventing the time-effect limitation of radiosurgery.
The low incidence of side effects of radiosurgery reported in this study supports the suggested approach as being safe, effective, and the primary approach for dural arteriovenous fistulas. The authors were able to demonstrate obliteration rate as high as 86% when their ''dream'' approach was followed. The authors must be congratulated for their good work. ural arteriovenous fistulas (DAVFs) are rare anomalies, which frequently are asymptomatic but occasionally can be quite symptomatic with progressive, pulsating exophthalmos, severe tinnitus, or intracranial hemorrhage, necessitating treatment in a timely fashion. It is consequently important for every neurosurgeon to be aware of the optimal treatment of this kind of cranial vascular malformation. With the increasingly well-documented efficacy of radiosurgery and embolization in combination, as demonstrated in this article, the role of open surgery is decreasing in the management of this condition.
Of interest is the order in which radiosurgery and embolization are best performed. Even though the number of observations in this study is not enough for a statistical analysis, it makes sense, as suggested by the authors, to start with the radiosurgery when the target, in general, is easiest to define and then proceed with the embolization.
The number of patients with unsuccessful complete obliteration or recanalization should decrease with the consistent use of glue and coils rather than particulate embolization. However, as demonstrated in this and other articles, embolization should always be combined with radiosurgery for optimal short-and long-term outcome.
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